View allAll Photos Tagged DrugDevelopment
A student measuring zones of inhibition
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Carol Ishimaru teaching students broad spectrum vs narrow spectrum activity in antibiotcs
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Linda Kinkel working with student in lab exercise.
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Students collection of data to see how effective each streptomyces isolate was against particular pathogens
Fill in your information:
[More information about the picture]
[Favorite story/memory about the picture]
Linda Kinkel discussing data with students
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Linda Kinkel and undergraduate student discussing data.
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Carol Ishimaru broad spectrum vs narrow spectrum activity in antibiotcs
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Carol Ishimaru and Linda Kinkel working with undergraduate student
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Undergraduate student evaluating her isolates.
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Get access to 150 unique GCP findings from www.gcpfinding.com/gcp-finding/
These findings will help: Clinical Research Associate – Ensuring GCP findings are captured during site monitoring visit
Clinical Trial Coordinator - To avoid GCP findings while completing study documents
Clinical Investigator- Keeping investigative site compliant with GCP requirements
Contact us for more details
GCP Finding | Clinical Research
LinkedIn: www.linkedin.com/company/66181788
Website: www.gcpfinding.com
Facebook: www.facebook.com/GCP-Finding-109859400786697
Email: info@gcpfinding.com
The training contains presentations that will allow participant to enjoy the learning process and easily understand the fundamentals of Good Clinical Practice. Also read ICH GCP E6 (R2) guideline contents through speaker notes.
Get your free web based certification on completion of training sessions and quiz.
Contact us for more details
GCP Finding | Clinical Research
LinkedIn: www.linkedin.com/company/66181788
Website: www.gcpfinding.com
Facebook: www.facebook.com/GCP-Finding-109859400786697
Email: info@gcpfinding.com
Get access to 150 unique GCP findings from www.gcpfinding.com/gcp-finding/
These findings will help:
Project Manager-Training team members on unique findings and ensuring compliance
CRA/QA Auditor – Ensuring GCP findings are captured during site visit
Study Investigator- Keeping investigative site compliant with GCP requirements
Registered Nurse/CRC- To avoid such GCP findings while completing study documents
Get access to 150 unique GCP findings from www.gcpfinding.com/gcp-finding/
These findings will help: Clinical Research Associate – Ensuring GCP findings are captured during site monitoring visit
Clinical Trial Coordinator - To avoid GCP findings while completing study documents
Clinical Investigator- Keeping investigative site compliant with GCP requirements
Contact us for more details
GCP Finding | Clinical Research
LinkedIn: www.linkedin.com/company/66181788
Website: www.gcpfinding.com
Facebook: www.facebook.com/GCP-Finding-109859400786697
Email: info@gcpfinding.com
This training product is crafted for those who are involved in conducting clinical trials, at the sponsor or CRO or at the Investigator site. Find out 150 unique GCP findings that cover everything from the essentials to more specialized topics in conducting clinical trials. With more than 500 pages, our GCP finding module covers the following topics:
• Informed Consent (39 Unique GCP Findings — 147 pages)
• Study Logs and Forms (31 Unique GCP Findings — 99 pages)
• Case Report Form (28 Unique GCP Findings — 105 pages)
• Source Documentation (27 Unique GCP Findings — 89 pages)
• Protocol Compliance (11 Unique GCP Findings — 52 pages)
• Ethics Committee (09 Unique GCP Findings — 35 pages)
• Investigational Product (05 Unique GCP Findings — 11 pages)
Contact us for more details
GCP Finding | Clinical Research
LinkedIn: www.linkedin.com/company/66181788
Website: www.gcpfinding.com
Facebook: www.facebook.com/GCP-Finding-109859400786697
Email: info@gcpfinding.com
Piramal Pharma Solutions is a reputed service provider for mg to gm scale drug discovery,/a> chemistry, have partnered with a range of well know pharmaceutical and biotechnology companies.
Author: Barış Kurt
Abstract: The main protease (Mpro or 3CLpro) plays important roles in viral replication and is one of attractive targets for drug development for SARS-CoV-2. In this study, we investigated the potential inhibitory effect of lycorine molecule as a ligand on SARS-CoV-2 using computational approaches. For this purpose, we conducted molecular docking and molecular dynamics simulations MM-PB(GB)SA analyses. The findings showed that the lycorine ligand was successfully docked with catalytic dyad (Cys145 and His41) of SARS-CoV-2 Mpro with binding affinity changing between -6.71 and -7.03 kcal mol-1. MMPB(GB)SA calculations resulted according to GB (Generalized Born) approach in a Gibbs free energy changing between -24.925-+01152 kcal/mol between lycorine and SARS-CoV-2 which is promising. PB (Poisson Boltzmann) approach gave less favorable energy (-2.610±0.2611 kcal mol-1). Thus, Entropy calculations from the normal mode analysis (ΔS) were performed and it supported GB approach and conducted - 23.100±6.4635 kcal mol-1. These results showed lycorine has a druggable potential but the drug effect of lycorine on COVID-19 is limited and experimental studies should be done with pharmacokinetic modifications that increase the drug effect of lycorine.
Keywords: Molecular Dynamics Simulation, MMPBSA, Gibbs Energy, SARS-CoV-2
Piramal Pharma Solutions offer comprehensive drug development services to help the customer address complex drug development challenges and bring more products to the market faster.
Development of new drugs in a pharma lab as part of a pharmaceutical research program. Developmental drugs are key to treating new illnesses. We should all look forward to new breakthroughs from pharmaceutical companies and medical science. Black and white photo of drugs.
Global Research Journal of Pharmaceutical and Drug Discovery
invites researchers, scientists, and scholars to publish high-quality research articles in the field of pharmaceuticals and drug discovery.
Submit your manuscript
Submit here: ucjournals.com/submit-manuscript/
Journal details: ucjournals.com/global-research-journal-of-pharmaceutical-...
Contact: wa.me/+971551792927
#PharmaceuticalResearch #DrugDiscovery #MedicalResearch #ResearchPublication #OpenAccessJournals #GlobalResearch #PharmaInnovation #DrugDevelopment #ResearchCommunity #PharmaScience #UCJournals #CallForPapers #ScientificJournals #PharmaResearch #InnovativeMedicine
Infinium Pharmachem has developed and maintained long-term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies & many more. Our products reach out to over 550+ clients globally.
To Inquire Us : www.infiniumpharmachem.com
Clinfinite Solutions is a leading provider of integrated technology solutions designed to optimize various stages of drug development. From pre-clinical trials to post-market surveillance, their suite of services caters to the diverse needs of pharmaceutical companies, research organizations, and regulatory agencies. These solutions are engineered to enhance efficiency, reduce costs, and accelerate the overall drug development timeline.
Visit Here:- www.clinfinite.com/service.php
In the fast-paced and ever-evolving world of pharmaceuticals, finding the right partner for drug development is crucial for success. Clinfinite Solutions emerges as a standout player, offering cutting-edge solutions that have garnered the trust of top pharmaceutical companies.
Visit Here:- www.clinfinite.com/service.php
MAGNA™, a new technology from Depixus, is revolutionizing RNA-targeted drug discovery. It uses magnetic force spectroscopy to study interactions between RNA and small molecules, helping researchers develop new therapeutics and avoid costly failures during drug development.
This training product is crafted for those who are involved in conducting clinical trials, at the sponsor or CRO or at the Investigator site.
Find out 150 unique GCP findings that cover everything from the essentials to more specialized topics in conducting clinical trials. With more than 500 pages, our GCP finding module covers the following topics:
• Informed Consent (39 Unique GCP Findings — 147 pages)
• Study Logs and Forms (31 Unique GCP Findings — 99 pages)
• Case Report Form (28 Unique GCP Findings — 105 pages)
• Source Documentation (27 Unique GCP Findings — 89 pages)
• Protocol Compliance (11 Unique GCP Findings — 52 pages)
• Ethics Committee (09 Unique GCP Findings — 35 pages)
• Investigational Product (05 Unique GCP Findings — 11 pages)
Contact us for more details
GCP Finding | Clinical Research
LinkedIn: www.linkedin.com/company/66181788
Website: www.gcpfinding.com
Facebook: www.facebook.com/GCP-Finding-109859400786697
Email: info@gcpfinding.com